Molecular targeting of renal cell carcinoma by an oral combination

The 5-year survival rate of patients with metastatic renal cell carcinoma (mRCC) is <12% due to treatment failure. Therapeutic strategies that overcome resistance to modestly effective drugs for mRCC, such as sorafenib (SF), could improve outcome in mRCC patients. SF is terminally biotransformed...

Descripción completa

Detalles Bibliográficos
Autores principales: Jordan, Andre R., Wang, Jiaojiao, Yates, Travis J., Hasanali, Sarrah L., Lokeshwar, Soum D., Morera, Daley S., Shamaladevi, Nagarajarao, Li, Charles S., Klaassen, Zachary, Terris, Martha K., Thangaraju, Muthusamy, Singh, Amar B., Soloway, Mark S., Lokeshwar, Vinata B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237463/
https://www.ncbi.nlm.nih.gov/pubmed/32427869
http://dx.doi.org/10.1038/s41389-020-0233-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237463/
https://www.ncbi.nlm.nih.gov/pubmed/32427869
http://dx.doi.org/10.1038/s41389-020-0233-0

Ejemplares similares